Artificial Intelligence (AI) is rapidly transforming the drug discovery process, turning hype into tangible real-world results. Companies like Iktos and VeriSIM Life, both part of our Innovation Fund’s portfolio, are at the forefront of revolutionizing drug design through cutting-edge AI technologies.
Iktos is harnessing the power of generative AI to accelerate drug discovery. With platforms like Makya for molecule design and Spaya for retrosynthesis, Iktos leverages AI to create innovative and efficient synthesis pathways. Their automated synthesis and high-throughput robotics allow for faster iteration and testing, drastically reducing the time needed to develop viable drug candidates.
On the other hand, VeriSIM Life is redefining clinical success prediction. Their hybrid platform, BIOiSIM, integrates AI with mechanistic models to predict drug performance in clinical trials without the need for extensive animal testing. By simulating organ systems across species, VeriSIM’s technology not only enhances efficacy but also significantly lowers R&D costs. Recently, they received FDA orphan drug designation for a breakthrough treatment for pulmonary arterial hypertension.
Both companies exemplify the tremendous potential of AI in healthcare, proving that the integration of innovative technologies is paving the way for faster, more accurate drug development.
Discover more here.